Form 4: Rapport Therapeutics Director Ramiro Sanchez Granted Stock Options

Rapport Therapeutics, Inc. Director Ramiro Sanchez was granted 10,925 stock options with an exercise price of $10.95, vesting over one year or upon the next annual meeting.

Summary

• Ramiro Sanchez, a Director of Rapport Therapeutics, Inc. (RAPP), was granted 10,925 stock options on June 17, 2025.
• The stock options have an exercise price of $10.95 per share.
• The options are set to expire on June 17, 2035.
• Vesting of these options will occur on the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, contingent on Mr. Sanchez's continued service.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating alignment of interests and a commitment to long-term value creation. It's a standard compensation practice, so not exceptionally positive, but certainly not negative.

Positives

• The grant of stock options to Director Ramiro Sanchez aligns his interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Negatives

• No specific negatives are identified in this Form 4 filing, which primarily reports an insider transaction.

Risks

• The vesting of the options is subject to the director's continued service, meaning the options could be forfeited if service ceases before vesting.
• The value of the options is dependent on the future stock price of Rapport Therapeutics, Inc. exceeding the exercise price of $10.95.

Future Outlook

The document indicates a future vesting schedule for the granted stock options, with vesting occurring on the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, subject to continued service.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, including companies like Rapport Therapeutics, Inc., to attract, retain, and incentivize key personnel by aligning their financial interests with long-term company performance and shareholder value creation. This practice is consistent with compensation strategies seen across publicly traded companies in the sector.

Comparison to Industry Standards

• The grant of stock options to a director is a standard component of executive and director compensation packages across various industries, including the pharmaceutical and biotechnology sectors.
• While specific grant sizes and vesting schedules vary by company size, stage, and individual role, the structure of this grant (time-based vesting, 10-year term) is typical.
• For instance, similar equity compensation structures are observed in companies like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors, though the scale of grants would differ based on market capitalization and compensation philosophy.
• Without specific peer compensation data, a direct quantitative comparison of the grant size is not feasible from this document alone, but the mechanism itself is standard.

Related Party Transactions

• The grant of 10,925 stock options to Director Ramiro Sanchez by Rapport Therapeutics, Inc. is a related party transaction, representing compensation for his service.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: While not directly impacting general employees, it reflects the company's compensation strategy for its leadership.
• Director (Ramiro Sanchez): Receives equity compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will vest on the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, subject to continued service.
• The director may exercise the options to acquire common stock at the exercise price of $10.95 per share at any time after vesting and before the expiration date of June 17, 2035.

Key Dates

Keywords

Rapport Therapeutics, RAPP, SEC Form 4, Insider Trading, Stock Options, Director Compensation, Beneficial Ownership, Equity Grant